Valuation: Crossject

Market Cap 97.35M 111M 89.46M 83.39M 158M 10.6B 161M 1.07B 418M 5.21B 418M 409M 17.96B P/E 2026 *
4.36x
P/E 2027 * 3.44x
Enterprise Value 79.45M 90.88M 73.01M 68.05M 129M 8.65B 131M 877M 341M 4.25B 341M 334M 14.66B EV / Sales 2026 *
1.31x
EV / Sales 2027 * 1.19x
Free-Float
89.86%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 63 07/08/2001
Director of Finance/CFO - 24/03/2026
Corporate Officer/Principal - 19/08/2024
Director TitleAgeSince
Chairman 67 25/06/2009
Director/Board Member 67 -
Director/Board Member - -
Change 5-day change 1-year change 3-year change Capi.($)
-17.93%-.--% - - 111M
+0.35%+4.34%-29.25%-68.65% 89.15M
-0.98%-2.73%+61.09%+5.01% 68.57M
Average -6.40%+0.80%+15.92%-31.82% 78.86M
Weighted average by Cap. -7.79%+1.27%+10.03%-36.62%

Financials

2026 *2027 *
Net sales 60.8M 69.55M 55.88M 52.08M 98.79M 6.62B 100M 671M 261M 3.26B 261M 255M 11.22B 42.3M 48.39M 38.87M 36.23M 68.73M 4.61B 69.77M 467M 181M 2.26B 182M 178M 7.8B
Net income 28.3M 32.37M 26.01M 24.24M 45.98M 3.08B 46.68M 312M 121M 1.52B 122M 119M 5.22B 7.75M 8.87M 7.12M 6.64M 12.59M 844M 12.78M 85.5M 33.24M 415M 33.28M 32.56M 1.43B
Net Debt -17.9M -20.48M -16.45M -15.33M -29.08M -1.95B -29.52M -197M -76.77M -958M -76.86M -75.21M -3.3B -47M -53.76M -43.19M -40.26M -76.36M -5.12B -77.52M -519M -202M -2.52B -202M -197M -8.67B
Logo Crossject
Crossject specializes in manufacturing and marketing needleless drug self-injection. The group provides Zeneo, a prefilled and single-use device that can be used for intradermal, subcutaneous and intramuscular injections.
Employees
99
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-